title: Role of endothelin-1 in acute lung injury.
abstract: The alveolar-capillary membrane serves as a barrier that prevents the accumulation of fluid in the alveolar space and restricts the diffusion of large solutes while facilitating an efficient gas exchange. When this barrier becomes dysfunctional, patients develop acute lung injury (ALI), which is characterized by pulmonary edema and increased lung inflammation that leads to a life-threatening impairment of gas exchange. In addition to the increase of inflammatory cytokines, plasma levels of endothelin-1 (ET-1), which is a primarily endothelium-derived vasoconstrictor, are increased in patients with ALI. As patients recover, ET-1 levels decrease, which suggests that ET-1 may not only be a marker of endothelial dysfunction but may have a role in the pathogenesis of ALI. While pulmonary edema accumulates, alveolar fluid clearance (AFC) is of critical importance, as failure to return to normal clearance is associated with poor prognosis in patients with pulmonary edema. AFC involves active transport mechanisms where sodium (Na(+)) is actively transported from the alveolar airspaces, across the alveolar epithelium, and into the pulmonary circulation, which creates an osmotic gradient that is responsible for the clearance of lung edema. In this article, we review the relevance of ET-1 in the development of ALI, not only as a vasoconstrictor molecule but also by inhibiting AFC via the activation of endothelial ET-B receptors and generation. Furthermore, this review highlights the therapeutic role of drugs such as beta-adrenergic agonists and, in particular, of endothelin receptor antagonists in patients with ALI.
authors.affiliation: Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA. alejandro-comellas@uiowa.edu
authors.forename: Alejandro P
authors.initials: AP
authors.lastname: Comellas
authors.forename: Arturo
authors.initials: A
authors.lastname: Briva
mesh_terms: D055371:Acute Lung Injury / Q000188:drug therapy / Q000503:physiopathology*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology*; D006801:Humans
chemical_list: D000318:Adrenergic beta-Agonists; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1